JP2013529619A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529619A5
JP2013529619A5 JP2013515902A JP2013515902A JP2013529619A5 JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5 JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013515902 A JP2013515902 A JP 2013515902A JP 2013529619 A5 JP2013529619 A5 JP 2013529619A5
Authority
JP
Japan
Prior art keywords
chloropyrimidin
thiazol
tert
butyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013515902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060561 external-priority patent/WO2011161216A1/en
Publication of JP2013529619A publication Critical patent/JP2013529619A/ja
Publication of JP2013529619A5 publication Critical patent/JP2013529619A5/ja
Pending legal-status Critical Current

Links

JP2013515902A 2010-06-25 2011-06-23 タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物 Pending JP2013529619A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35860310P 2010-06-25 2010-06-25
US61/358,603 2010-06-25
US36853410P 2010-07-28 2010-07-28
US61/368,534 2010-07-28
PCT/EP2011/060561 WO2011161216A1 (en) 2010-06-25 2011-06-23 Heteroaryl compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2013529619A JP2013529619A (ja) 2013-07-22
JP2013529619A5 true JP2013529619A5 (enExample) 2014-07-24

Family

ID=44280749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515902A Pending JP2013529619A (ja) 2010-06-25 2011-06-23 タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物

Country Status (11)

Country Link
US (1) US20130096149A1 (enExample)
EP (1) EP2585454A1 (enExample)
JP (1) JP2013529619A (enExample)
KR (2) KR20130048293A (enExample)
CN (1) CN103080107A (enExample)
AU (1) AU2011268906A1 (enExample)
BR (1) BR112012032884A2 (enExample)
CA (1) CA2803055A1 (enExample)
EA (1) EA201201676A1 (enExample)
MX (1) MX2012015100A (enExample)
WO (1) WO2011161216A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2678336B1 (en) * 2011-02-24 2016-04-20 Nerviano Medical Sciences S.r.l. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018055097A1 (en) 2016-09-23 2018-03-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
AU2020276695B2 (en) 2019-05-13 2025-12-18 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
KR20220131229A (ko) 2019-12-05 2022-09-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도
CN111320548B (zh) * 2020-04-24 2022-10-18 浦拉司科技(上海)有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
EP4281436A1 (en) * 2021-01-20 2023-11-29 Basf Se Synthesis of polyfluorinated aryl and heteroaryl carboxamides
KR20240167846A (ko) 2022-03-28 2024-11-28 니캉 테라퓨틱스 인코포레이티드 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
JP2003063993A (ja) * 2001-06-11 2003-03-05 Takeda Chem Ind Ltd 医薬組成物
PT1482932E (pt) 2002-03-13 2010-01-12 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
GT200500287A (es) 2004-10-13 2006-04-17 Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
MX2007010404A (es) 2005-02-25 2008-01-11 Kudos Pharm Ltd Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
EP1871377A1 (en) 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
AU2006318948B2 (en) 2005-11-22 2011-02-24 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
SG183036A1 (en) * 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2231625A4 (en) * 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
WO2011059610A1 (en) * 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds

Similar Documents

Publication Publication Date Title
JP2013529619A5 (enExample)
JP2010505891A5 (enExample)
LT3034497T (lt) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas
JP2014138100A5 (enExample)
DK2683708T3 (da) Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
JP2015512729A5 (enExample)
JP2015522045A5 (enExample)
JP2013514381A5 (enExample)
LT3127540T (lt) Tam tikri aminopiridinai, jų kompozicijos ir jų panaudojimo būdai
JP2014513036A5 (enExample)
JP2013522425A5 (enExample)
TWD162694S (zh) 溫度計(一)之部分(衍生二)
TWD162693S (zh) 溫度計(一)之部分(衍生一)
JP2011527428A5 (enExample)
BR112015023218A2 (pt) formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
EA201370149A1 (ru) Антагонисты рецептора
JP2014521346A5 (enExample)
GEP20156397B (en) Process for the preparation of a rivaroxaban and intermediates formed in said process
JP2017092104A5 (enExample)
UY33511A (es) Procedimiento de obtención de la forma cristalina ii del febuxostat
PH12015502486A1 (en) N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides
JP2010208011A5 (enExample)
JP2017518319A5 (enExample)
JP2017500530A5 (enExample)